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European diabetes research: the need for strategic
planning
As already discussed in this journal [1] and elsewhere [2],
there is a critical need for more funds for diabetes research in
Europe. But for any such investment to pay dividends, there
must be a strategic plan for the sustainable development of
diabetes research in Europe, with better coordination of such
research and more rational (science-based) use of funds, for
the benefit of individuals with diabetes. The established
approach to research we have today in Europe, with largely
random and uncoordinated investment, stifles European
research competitiveness. The new European Commissioner
for Research and Innovation recognises the problem [3].
To succeed without causing collateral damage, a strategic
research plan must not divert funds from pure academic
research, which must continue to drive great discoveries as it
has throughout history. Provided that investment in research is
increased—as is the declared intent of the European Commis-
sion and many national governments as part of the Europe
2020 strategy [4] (and which we hope is not doomed to
failure like the preceding 10 year Lisbon Strategy)—a
strategic research plan and pure academic research are
complementary, rather than mutually exclusive, approaches
to research funding.
DIAMAP: a road map for diabetes research in Europe
Recognising the magnitude of the diabetes problem and the
specific research challenges and opportunities it presents to
Europe, the Health Directorate of the European Commis-
sion Directorate General for Research issued a call for
projects in the 7th Framework Programme (FP7) that would
develop a road map for diabetes research. DIAMAP, the
project submitted by EURADIA, the Alliance for European
Diabetes Research (www.euradia.org), was accepted for
funding [1].
The DIAMAP road map project is now complete. The
report, road maps and databases are publicly accessible at
www.diamap.eu.
What is DIAMAP? There are two components to the
project. The road maps are intended to guide future
investment in diabetes research by the European Commis-
sion and any other organisation or company interested in this
strategic plan. The maps cover research areas considered by
a group of leading experts to offer the greatest scientific
interest and potential for advancing the field, ultimately for
benefit to the patient. This new strategy for European
diabetes research is rational, science-driven and takes into
consideration the unique expertise and opportunities in
Europe.
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The databases provide a snapshot of research that is
ongoing in the European region today as well as the amount
of money devoted to diabetes research in Europe and the
major sources of such funding.
The road maps The road maps cover diabetes research in
the very broadest sense, from molecular studies to clinical
science and healthcare delivery. The DIAMAP teams were
multidisciplinary, with experts from all research communi-
ties. There is an emphasis on the need to coordinate
diabetes research in Europe, including an ambitious
proposal to create a central European resource to facilitate
clinical research.
The groups (see www.diamap.eu for a list of experts)
developed their road maps using a common strategy. Major
advances in each field served as entry points for the
research tracks with overarching goals for future research as
the endpoints; interim research milestones chart progress
along each track with roadblocks identified that prevent
progress (Fig. 1). Goals or specific milestones that were
considered particularly important for advancement in the
field, with readily available European know-how, are
flagged as priorities. The Horizontal Issues group worked
in parallel, addressing crosscutting and generic issues, such
as ethics and training.
The databases The research database is a unique, fully
interactive resource providing detailed information on who
is doing what and where in diabetes research in Europe. It
also provides information on specific resources or techni-
ques used by these investigators. The funding database
contains information obtained from national and interna-
tional public and charitable funding agencies and provides
unique insight into the landscape of diabetes research
funding in Europe, with data for most European countries,
including best estimates of the total annual investment in
diabetes research in Europe. Confidentiality was strictly
respected in developing the public databases.
Who should benefit from DIAMAP? What are its possible
weaknesses? All stakeholders in Europe interested in any
aspect of diabetes research should benefit from DIAMAP:
patients, researchers from all disciplines and subspecialities
related to the disease, payers and science policy-makers.
With the (admittedly very ambitious) proviso that major
funding agencies adopt the road map strategy and manage
to coordinate their funding, ideally through a central
resource such as EURADIA, DIAMAP could have a huge
and very positive impact on diabetes research in Europe. It
would allow European diabetes research to be better
coordinated and focused than ever before, making the
whole enterprise more rational and cost-effective, ensuring
greater benefit to individuals with diabetes.
That being said, some may not appreciate DIAMAP or
these potential benefits right away: they will cry foul!
Researchers are notoriously protective of their academic
independence. Any top-down approach that restricts fund-
ing to specific areas of research is contested and resented.
That is exactly why it is so important to guarantee that
funding for investigator-initiated research is not impacted
by a strategic plan such as DIAMAP. Equally, funding
agencies, especially those with a very focused mission,
consider themselves best able to identify research most
likely to benefit their own constituency. DIAMAP will
allow them to do so by selecting milestones from the road
maps. The final choice will still be theirs but in the
knowledge that it is supported by an outstanding group of
outside experts.
There are surely some weaknesses. Like any academic
exercise, the value of DIAMAP depends on the expertise,
selflessness and vision of those contributing to the project.
While their remit was to be as broad-ranging and objective
as possible, no project such as this can be all-embracing.
The experts spent a lot of time and effort creating the maps,
always keeping in mind potential benefit for the patient
while taking into consideration feasibility and specific
opportunities for European science. Are there holes in the
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Fig. 1 Example of a road map. In this example, a single entry point
(Milestone 1) leads to two parallel tracks (Milestones 2, 3 and 4, 5)
that each advance towards a common endpoint or overarching goal.
Actual tracks from each road map feature alternative (simpler or more
complex) layouts of the milestones, with the purpose of moving
research from the entry point(s) to a common endpoint. Only the most
specific and critical roadblocks are indicated in the tracks. *Mile-
stones/tracks that are considered to be especially important to the field,
as well as appropriate for immediate investment with the necessary
expertise and technology already in place, are indicated as a priority
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road maps? There surely are. Is it possible to second-guess
this group of experts and come up with another set of maps,
with different tracks and endpoints? Of course! But this is
not an absolute science. DIAMAP was never intended to
provide a definitive diabetes research road map; there can
be no such thing, but this should not make the strategy less
useful. This must be a continuously evolving story, with
feedback from all communities allowing improvement and
refinement in an iterative process.
The challenge for the databases was to capture relevant
information from all European senior/independent inves-
tigators and funding agencies. The research database does
provide a usefully representative snapshot in time of
European diabetes research, even if it certainly does not
feature every independent investigator working in the field
in Europe (not from lack of trying). The funding database
was a particular challenge. Although the information is both
extensive and useful thanks to the extraordinarily hard work
of the DIAMAP staff, it is not complete, especially at the
level of national government funding. Perhaps such a
survey of research funding can only succeed if undertaken
by a central authority: civil servants would be encouraged
to seek the relevant information if the request came from on
top, through their ministry in response to the European
Commission. In any case, data acquisition and analysis
must continue for both databases to make them even more
informative and to ensure that they remain up to date.
Ultimately, the success of this road map strategy will
depend not only on the quality of the maps but also on how
they are used. Aside from the obvious and primary goal of
guiding the choice of research areas for future investment,
in the longer term such a strategy cannot succeed unless
there is constant monitoring of progress and some way to
ensure that the European diabetes research effort is coordi-
nated. This could best be achieved by the creation of a central
entity, a virtual European Diabetes Institute. Such an institute
would not perform research itself and neither would it
provide funds. It would ensure that European diabetes was
coordinated, and would monitor progress in the various
DIAMAP research tracks and refine them as mentioned
above. This would allow Europe to capitalise fully on the
initial investment in this unique endeavour.
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